Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : STOCKS WITH ATTITUDE TEAM - FA/TA AND EVERYTHING ELSE -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (1907)	1/26/1998 3:46:00 PM
From: David Graham	Read Replies (1) \| Respond to of 2377

Segio, Jim, Mike and All, I have some more info on DSCO. They have four drugs in the pipeline in various stages of developement. 1 for adult respitory distress, 1 for meconium aspiration syndrome, 1 for cystic fibrosis and one for acute pancreatitis. ST-630 is for osteoporosis. All are past phase one and are for virgin markets. Surfaxin is nearing completion of phase two for MAS and ARDS. They have 13 million in cash and a very low burn rate. Management is a whos who of the bio-tech and financial world, most noteable is David Crockord, formerly with Alpha 1 and Oncologix where he brought 19 products to the FDA and all were approved. Their web page can be accessed at www.discoverylabs.com Grammy